PLEASANTON, Calif.–(BUSINESS WIRE)–Clarity Medical Systems, Inc. announced today the hiring of several new key members of its Executive Leadership Team. These executives will initially focus on the commercial introduction of Clarity’s upcoming product, HOLOS IntraOP™, a continuous real-time intraoperative aberrometer for refractive cataract surgery. Clarity is a leader in the development, manufacturing, and marketing of integrated optical systems and services that enhance the clinician’s abil
LEXINGTON, Mass.–(BUSINESS WIRE)–ITEK Announces completion of $79 million offering
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/t595n6/dry_atrophic) has announced the addition of the “Dry (Atrophic) Macular Degeneration-Pipeline Insights” report to their offering. Summary Dry (Atrophic) Ma…
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three months and six months ended June 30, 2015, and provided a business update. Quarterly and Recent Operational and Financial Highlights Grew sales of Avenova™ Lid and Lash Cleanser by 73% to $806,000 in the second quarter of 2015 ove
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics Reports Second Quarter 2015 Financial Results. Management to host conference call today at 8:30 a.m. ET.
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation prices $68.9 million public offering
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporations Announces Second Quarter 2015 Financial Results
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Announces Date for Special Stockholder Meeting
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2015. “We continued to make strong progress in our development programs this quarter and look forward to several significant clinical milestones expected during the second half of 2015. For our lead product candid
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced today that it is approaching completion of patient enrollment of its U.S. Food and Drug Administration (FDA) pivotal study…
IRVINE, Calif., BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Canaccord Genuity Growth Conference on Wednesday, August 12, 2015 at 12:30 p.m. Eastern Time in Boston, MA. Dr. Anido’s presentation will include an Aerie overview and business update. The presentation will be webcast live and may be accessed by visiting A
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the second quarter ended June 30, 2015 along with a general business update. Aerie Highlights Efficacy results from Aerie’s RhopressaTM Rocket 2 trial, using the primary clinical endp
IRVINE, Calif. & BALTIMORE–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, and GrayBug, Inc., a venture-stage pharmaceutical company developing microparticle controlled release drug delivery technologies for the treatment of ocular diseases including wet age-related macular degenera
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2015. Bruker’s revenues for the second quarter of 2015 were $396.0 million, a decline of 13.4 percent compared to the second quarter of 2014. Excluding a 2.6 percent negative effect from divestitures, and an 11.5 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 0.7 percent in the second
BRUSSELS / SOMERSET, N.J.–(BUSINESS WIRE)–European Pricing Platform® (EPP) and its forum partner, Alliance Life Sciences, announce the upcoming 5th EPP Life Sciences Pricing Forum, 21 – 23 September, Montreux.
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous sy…
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today reported financial results for the three-month period ended June 30, 2015. Second Quarter 2015 Highlights Grew net revenue by 335% to $2.7 million in the second quarter of 2015, compared to $0.6 million in the prior year period; Implanted 20 Argus® II s
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near vision restoration announced today the appointment of Marie Cha as Director of Direct Response Marketing. Ms. Cha brings extensive experience in consumer marketing, with a strong focus on digital platforms. Ms. Cha will be responsible for overseeing the development and expansion of direct response marketing for the Presbia Flexivue Microlens™, a proprietary optical lens implant for treating pres
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics will report second quarter 2015 financial results Thursday, August 13, 2015 and host a conference call and audio webcast at 8:30 a.m. ET that same day.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report se…